Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTelescope Innovations Corp.

Telescope Innovations Corp.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.325 CAD 0.01 ( 1.56%)
Last update at 2026-11-04T19:49:00Z
VOLUME
16261
Market Cap
30.71M

Momentum Score

…

Telescope Innovations Corp., a chemical technology company, develops manufacturing processes and tools for the pharmaceutical and chemical industry in the United States and Canada. It offers DIRECTINJECT-LCTM, a hardware and software ecosystem that enables direct sampling and analysis of chemical reactions. It also provides intellectual property and contract research services. It serves pharmaceutical, critical minerals, and chemical industries. Telescope Innovations Corp. has a research collaboration with Pfizer Inc; and Standard Lithium Ltd. to develop a method for producing high-purity lithium sulfide. Telescope Innovations Corp. has a development and collaboration agreement with AGI Group's Synthesis, Digitization, and Automation program to develop the next generation of automation- and AI-ready chemical reactor technology. Telescope Innovations Corp. is based in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.33
Low
0.33
High
52 Week Price Range
0.23
Low
0.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Telescope Innovations Corp. (TELI.CN) is limited; regulatory filings and corporate disclosures available to investors are sparse, preventing a clear, verified description of its core business and financial position. Investors may find the company attractive only if future filings demonstrate a scalable business model or proprietary assets, but such prospects cannot be assessed from current public records.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.32
Dividend Yield
-
Revenue TTM
7.11M
Revenue Per Share
0.11
Gross Profit TTM
7.11M
Debt / Equity
-
ROE
-120.47%
Net Debt
-0.72M
ROCE
-32.71%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -1.56M -1.32M -0.72M -5.75M -4.03M
Net income -1.56M -1.32M -0.72M -5.73M -4.03M
Selling general administrative 4.44M 2.97M 2.33M 5.60M 3.72M
Selling and marketing expenses - - - 0.01M 0.00M
Gross profit - - 2.82M 0.60M -0.02M
Reconciled depreciation 0.72M 0.63M 0.30M 0.28M 0.00M
Ebit - - - -5.77M -
Ebitda - - - -5.49M -4.02M
Depreciation and amortization - - - 0.28M -
Operating income -1.35M -1.05M -0.72M -5.77M -4.02M
Other operating expenses - - - 6.35M 4.02M
Interest expense 0.25M 0.24M 0.00M 0.02M -
Net interest income -0.25M -0.24M 0.00M - -
Income tax expense - - - -0.02M 0.00M
Total revenue 4.78M 4.27M 2.82M 0.60M 0.00M
Total operating expenses 6.13M 5.31M 3.55M 6.35M 4.02M
Cost of revenue - - 0.00M 0.93M 0.02M
Total other income expense net 0.04M -0.04M 0.00M 0.02M -0.00M
Net income from continuing ops -1.56M -1.32M -0.72M -5.75M -4.03M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 7.28M 5.69M 3.29M 3.02M 4.07M
Other current assets - - - 0.06M -
Total liab 5.27M 4.17M 0.71M 1.35M 0.25M
Total stockholder equity 2.00M 1.52M 2.58M 1.67M 3.83M
Other current liab - - - 0.04M -
Common stock - - - 8.95M 8.10M
Capital stock 10.34M 10.34M 10.34M 8.95M 8.10M
Retained earnings -13.63M -12.07M -10.74M -10.02M -4.28M
Cash 2.70M 0.34M 0.36M 0.72M 3.29M
Total current liabilities 3.16M 2.15M 0.71M 1.35M 0.25M
Current deferred revenue - - - 0.83M -
Net debt - - - -0.72M -3.29M
Short long term debt 1.21M - - - -
Total current assets 3.84M 2.41M 1.21M 1.50M 3.47M
Net receivables 0.20M 1.55M 0.22M 0.72M 0.06M
Inventory 0.60M 0.30M 0.25M 0.00M -
Accounts payable 1.15M 0.40M 0.18M 0.48M 0.25M
Accumulated other comprehensive income - - - 2.74M -
Non current assets total 3.43M 3.29M 2.08M 1.53M 0.60M
Capital lease obligations 2.25M 2.03M 0.00M - -
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Investments - -0.04M -0.04M -1.20M -0.60M
Net borrowings 1.21M 0.00M - 0.00M -0.01M
Total cash from financing activities 3.04M 0.00M 1.43M 0.00M 4.79M
Net income -1.56M -1.32M -0.72M -5.75M -4.03M
Change in cash 2.36M -0.02M -0.36M -2.57M 3.25M
Begin period cash flow 0.34M 0.36M 0.72M 3.29M 0.05M
End period cash flow 2.70M 0.34M 0.36M 0.72M 3.29M
Total cash from operating activities 0.25M 0.02M -1.76M -1.37M -0.94M
Issuance of capital stock - 0.00M 1.43M 0.00M 4.79M
Depreciation 0.72M 0.63M 0.30M 0.28M 0.00M
Change to inventory -0.29M -0.06M -0.25M 0.00M -
Change to account receivables 1.35M -1.33M 0.28M -0.50M 0.00M
Other cashflows from financing activities - - - -1.20M 0.00M
Capital expenditures 0.92M 0.04M 0.04M 1.20M 0.60M
Change in working capital 0.87M 0.45M -1.54M 0.51M -0.03M
Stock based compensation 0.22M 0.26M 0.19M 2.74M 0.05M
Other non cash items - - - 0.85M 3.06M
Free cash flow -0.67M -0.02M -1.79M -2.57M -1.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TELI
Telescope Innovations Corp.		 0.01
1.56%		 0.33 - - 4.32 6.45 4.32 -1.62
DRUG
Bright Minds Biosciences Inc		 -10.97
29.58%		 26.11 - - - 13.50 - -0.10
METX
ME Therapeutics Holdings Inc.		 -0.05
4.55%		 1.05 - - - 72.00 - -
DTC
Defence Therapeutics Inc		 -0.01
1.47%		 0.34 - - - 89.80 - -9.99
LOBE
Lobe Sciences Ltd		 -
-%		 0.04 - - 2.44 15.58 5.75 1.64

Profile*

Telescope Innovations Corp.

Telescope Innovations Corp., a chemical technology company, develops manufacturing processes and tools for the pharmaceutical and chemical industry in the United States and Canada. It offers DIRECTINJECT-LCTM, a hardware and software ecosystem that enables direct sampling and analysis of chemical reactions. It also provides intellectual property and contract research services. It serves pharmaceutical, critical minerals, and chemical industries. Telescope Innovations Corp. has a research collaboration with Pfizer Inc; and Standard Lithium Ltd. to develop a method for producing high-purity lithium sulfide. Telescope Innovations Corp. has a development and collaboration agreement with AGI Group's Synthesis, Digitization, and Automation program to develop the next generation of automation- and AI-ready chemical reactor technology. Telescope Innovations Corp. is based in Vancouver, Canada.

301 - 2386 East Mall, Vancouver, BC, Canada, V6T 1Z3

778-262-1166

https://telescopeinnovations.com

Name Title Year Born
Mr. Henry Dubina CEO & Chairman of Board NA
Mr. John Kirincic Chief Financial Officer NA
Prof. Jason Hein CTO & Director NA
Ms. Vaso Vlachos Chief Operating Officer NA
Shad Grunert Senior VP of Sales & Marketing NA
Ms. Deborah Cotter Company Secretary NA
Mr. Jerry Chu Controller NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…